Peficitinib, a experimental drug targeting the spleen tyrosine kinase pathway , represents a significant advance in the management of rheumatoid arthritis . Early clinical trials suggest that it can https://peficitinib255621.newsyblog.com/187933/peficitinib-a-new-treatment-for-rheumatoid-joint-disease